BioNTech SE (BNTX) Stock

About BioNTech SE

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.

BioNTech SE is headquartered in DE.

BioNTech SE (BNTX) stock trades at $90.07 with a market capitalization of $22.78B. The stock is valued at a price-to-earnings (P/E) ratio of -15.45, price-to-book of 1.06, price-to-sales of 7.05. Over the past 52 weeks the stock has ranged between $79.52 and $124.00, and currently trades 27.4% below its 52-week high.

On profitability, BioNTech SE generates a return on equity (ROE) of -6.67%, return on capital employed of -7.54%, an operating margin of -52.06%, a net profit margin of -44.67%.

In its most recent fiscal year, BioNTech SE reported annual revenue of $2.8B, net profit of $-1.1B, revenue has compounded at 41.7% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 0.02 — a conservative balance sheet with little leverage risk, a current ratio of 8.80, total assets of $22.0B, $7.7B in cash and equivalents.

BNTX has an average daily trading volume of 958,473 shares, a beta of 1.32 (more volatile than the overall market).

Official website: www.biontech.de